59 results
S-3ASR
OCUL
Ocular Therapeutix Inc
25 Mar 24
Automatic shelf registration
4:40pm
insert) for the chronic treatment of dry eye disease, and several preclinical programs.
Corporate Information
We were incorporated under the laws … eye disease, and OTX-CSI for the chronic treatment of dry eye disease;
our commercialization efforts for our product DEXTENZA;
our plans to develop
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
11 Mar 24
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
4:10pm
) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
22 Feb 24
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
7:34am
(cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term
424B5
OCUL
Ocular Therapeutix Inc
14 Dec 23
Prospectus supplement for primary offering
4:09pm
health that
S-3
could make the drug suitable for chronic dosing, at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting in April … to four months in order to increase tear production for the chronic treatment of dry eye disease. We have completed a Phase 2 clinical trial evaluating
8-K
EX-99.1
ak73x8zm 4w
14 Dec 23
Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock
8:46am
424B5
z1t07m1l
13 Dec 23
Prospectus supplement for primary offering
4:10pm
8-K
EX-99.1
jwjau49 qw0541caxw
7 Nov 23
Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update
4:04pm
8-K
EX-99.1
figqdlizflidt0f viwj
7 Aug 23
Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update
4:06pm
8-K
EX-99.1
k7pxvcs7as w2
8 May 23
Ocular Therapeutix™ Provides First Quarter 2023 Financial Results and Corporate Update
4:04pm
8-K
EX-99.1
kbaoftr0
7 Nov 22
Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update
4:04pm
8-K
EX-99.1
ha2vemrwr766capp
8 Aug 22
Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update
4:09pm
8-K
EX-99.1
swf8mu940cwq3 r379q
9 May 22
Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
4:05pm